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Objective: To propose a novel ultrasound scoring system for hand and wrist joints (US10) for
evaluation of patients with early rheumatoid arthritis (RA) and to correlate the US10 with
clinical, laboratory and functional variables.
Methods: Forty-eight early RA patients underwent clinical and laboratory evaluations as
well  as blinded ultrasound (US) examinations at baseline, three, six and 12 months. The
proposed US10 system involved the assessment of the wrist, second and third metacar-
pophalangeal and proximal interphalangeal joints. The score consisted of inﬂammation
parameters (synovial proliferation [SP], power Doppler [PD] and tenosynovitis [TN]) and joint
damage parameters (bone erosion [BE] and cartilage damage [CD]). SP, PD, BE and CD were
scored qualitatively (0–1) and semi-quantitatively (grades 0–3). Tenosynovitis was scored as
presence/absence. The evaluation also involved the 28-Joint Disease Activity Score (DAS28),
Health Assessment Questionnaire (HAQ) and C-reactive protein level (CRP).
Results: Mean duration of symptoms was 7.58 ± 3.59 months. Signiﬁcant correlations
(p  < 0.05) were found between inﬂammation parameters and CRP at baseline and between
the  changes in these variables throughout the study. Signiﬁcant correlations (p < 0.05) werefound between DAS28 score and both PD and TN at baseline and between the changes in
DAS28 score and both SP and TN throughout the follow up. Moreover, signiﬁcant correla-
tions were found between the changes in inﬂammation parameter scores and HAQ score
throughout the follow up.∗ Corresponding author.
E-mail: jnatour@unifesp.br (J. Natour).
ttp://dx.doi.org/10.1016/j.rbre.2016.07.006
255-5021/© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/4.0/).
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Conclusion: The proposed US10 scoring system proved to be a useful tool for monitoring
inﬂammation and joint damage in early RA patients, demonstrating signiﬁcant correlations
with longitudinal changes in disease activity and functional status.
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Novo  sistema  de  escore  ultrassonográﬁco  (US10)  musculoesquelético  das
articulac¸ões  das  mãos  e  punho  para  avaliac¸ão  de  pacientes  com  artrite
reumatoide  em  fase  inicial
Palavras-chave:
Artrite reumatoide em fase
inicial
Mão
Ultrassom
Escore
r  e  s  u  m  o
Objetivo: Propor um novo sistema de escore ultrassonográﬁco das articulac¸ões da mão e
punho (US10) para a avaliac¸ão de pacientes com artrite reumatoide (AR) e correlacionar o
US10  com variáveis clínicas, laboratoriais e funcionais.
Métodos: Foram submetidos 48 pacientes com AR em fase inicial a avaliac¸ões clínicas e lab-
oratoriais, bem como a exames cegos de ultrassom (US) no início do estudo e com 3, 6 e
12  meses. O sistema US10 proposto envolveu a avaliac¸ão do punho e das articulac¸ões
metacarpofalângicas e interfalângicas proximais do segundo e terceiro dígitos. O escore
consistiu em parâmetros inﬂamatórios (proliferac¸ão sinovial [PS], Power Doppler [PD] e
tenossinovite [TN]) e parâmetros de danos articulares (erosão óssea [EO] e danos na
cartilagem [DC]). PS, PD, EO e DC foram pontuados qualitativamente (0 a 1) e semiquantita-
tivamente (graus 0 a 3). A tenossinovite foi pontuada como presenc¸a/ausência. A avaliac¸ão
envolveu também o escore 28-Joint Disease Activity (DAS28), o Health Assessment Questionnaire
(HAQ) e o nível de proteína C-reativa (PCR).
Resultados: A durac¸ão média dos sintomas foi de 7,58 ± 3,59 meses. Foram encontradas
correlac¸ões  estatisticamente signiﬁcativas (p < 0,05) entre os parâmetros de inﬂamac¸ão e a
PCR no início do estudo e entre as mudanc¸as nessas variáveis ao longo do estudo. Foram
encontradas também correlac¸ões signiﬁcativas (p < 0,05) entre o escore DAS28 e a PD e TN
no  início do estudo e entre as mudanc¸as no escore DAS28 e PS e TN em todo o seguimento.
Além disso, foram encontradas correlac¸ões signiﬁcativas entre as mudanc¸as no escore dos
parâmetros de inﬂamac¸ão e no escore HAQ ao longo do seguimento.
Conclusão: O sistema de escore US10 proposto provou ser uma ferramenta útil para mon-
itorar a inﬂamac¸ão e o dano articular em pacientes com AR em fase inicial, demonstra
correlac¸ões  signiﬁcativas com as alterac¸ões longitudinais na atividade da doenc¸a e no estado
funcional.
© 2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC
BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In recent years, musculoskeletal ultrasound (US) has been
employed for monitoring patients with rheumatoid arthri-
tis (RA) with regard to both disease activity and joint
damage.1–6 Disease activity is evaluated using gray-scale
and Power Doppler (PD) synovitis and tenosynovitis.4,5,7,8
However, there is no consensus on the US evaluation of
synovitis (synovial proliferation and PD) in the joints, as
scoring is performed with either a binary variable (pres-
ence/absence of synovitis) or a semi-quantitative variable
(usually using a scale from 0 [absence of synovitis] to 3 [severe
synovitis]).9–14
US can also be used to assess joint damage and has proven
to be sensitive to the detection of bone erosion, which isimportant to the diagnosis and evaluation of RA, especially in
small joints of the hands and feet.6,10 Indeed, US  is better able
to detect erosions in the metacarpophalangeal joints (MCPs)
in patients with early RA than radiography.6 Like synovitis,
bone erosion can be evaluated using a semi-quantitative
scoring system, with excellent interobserver agreement
(ICC = 0.78 and k = 0.68).10
A number of studies have evaluated different simpliﬁed
scores and report satisfactory correlations with clinical dis-
ease activity indices.15–18 The joints of the hands (proximal
interphalangeal PIPs and MCPs) and wrist are the most affected
in early RA and are systematically assessed through physical
examinations and for treatment decision.19–22 However, there
is insufﬁcient evidence on which joints and synovial recesses
are better for the US detection of synovitis. The prospec-
tive investigation of a simpliﬁed US scoring system for these
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the lowest value, while color gain was increased to ther e v b r a s r e u m a t o l
oints in disease-modifying antirheumatic drugs (DMARD)-
aïve patients with early RA may be useful to clinical follow-up
nd for monitoring therapy.
Thus, the aim of the present study was to investigate a
ovel US scoring system for the evaluation of inﬂammation
nd joint damage in the hand and wrists joints, denominated
he US10, and correlate US inﬂammation and joint damage
arameters with clinical, laboratory, functional and radio-
raphic ﬁndings in patients with early RA over a 12 months
f follow up.
atients  and  methods
atients
 prospective cohort study was conducted involving 48
onsecutive patients with early RA, with symptom dura-
ion for more  than six weeks and less than one year
ince onset. The individuals were recruited from Rheuma-
ology Outpatient Clinics of the Universidade Federal de São
aulo. This study received approval from the Research Ethics
ommittee.
The inclusion criteria were the following: diagnosis of RA
ased on the 1987 and 2010 classiﬁcation criteria of the Amer-
can College of Rheumatology (ACR) or a cutoff point of ≥8.0
n predictive validation Leiden model score.23,24 The Leiden
core consists of nine clinical and laboratory variables includ-
ng age, sex, location of joint symptoms, morning stiffness,
ender and swollen joint count, CRP levels and presence of RF
nd anti-CCP antibody. Each item has a value, and the varia-
ion of 0–14 score. A patient is classiﬁed as early RA if presents
 score ≥8.25
The exclusion criteria were the following: previous treat-
ent with DMARDs, use of oral glucocorticoid >10 mg/d in
he previous three weeks or a parenteral glucocorticoid in
he previous four weeks, serum aspartate aminotransferase
r alanine aminotransferase level >3 times the upper limit
f normal, bone marrow hypoplasia, overlap with any other
ollagen disease, suspicion of lymphoproliferative disease,
ositive serology for hepatitis B or C and pregnancy.
All patients underwent clinical, laboratory and US evalua-
ions at baseline, three, six and 12 months. A tightly controlled
herapeutic protocol was used for all patients by a single
heumatologist who was blinded to the US evaluation. The
atients began with methotrexate (MTX) 15 mg/week, which
as increased to 25 mg/week in the ﬁrst three months. Subse-
uent steps for patients with an insufﬁcient response (DAS28
core > 3.2 and evaluator-based global assessment of disease
ctivity score > 4.0 [0–10 cm]) were leﬂunomide with MTX
5 mg/week, leﬂunomide and MTX  25 mg/week, adalimumab
nd MTX  15 mg/week and, ﬁnally, MTX  15 mg/week with a sec-
nd biologic agent.
linical  assessmenthe patients were clinically evaluated during each visit.
wenty-eight joints (bilateral PIPs, MCPs, wrists, elbows,
houlders and knees) were clinically assessed for swelling
nd tenderness. The following instruments were also 6;5 6(5):421–431 423
employed: Evaluator based global assessment of disease activ-
ity (0–10 cm); patient based global assessment of disease
activity (0–10 cm); Brazilian version of the functional subscale
of the Stanford Health Assessment Questionnaire (HAQ)26;
and the 28-Joint Disease Activity Score (DAS28).
Laboratory  evaluation
The dosage of C-reactive protein (CRP) level (mg/dliter) and
erythrocyte sedimentation rate (ESR) (mm/hour) were deter-
mined at each visit. IgM rheumatoid factor and anti-cyclic
citrullinated peptide (anti-CCP) antibodies were assessed at
baseline.
Ultrasound  assessment
The US examination was performed by a trained rheumatol-
ogist with eight years of experience in US who was blinded
to all other study ﬁndings. US examinations were performed
using a MyLab60 (Esaote, Biomedica – Genoa, Italy), equipped
with a broadband linear probe with frequency ranging from 6
to 18 MHz.
Systematic multiplanar gray-scale US (GSUS) and PD exam-
inations were performed on 10 joints (wrist, MCP2, MCP3, PIP2
and PIP3 in both hands) in a standardized manner based on
the guidelines of the European League Against Rheumatism.27
All joint regions were assessed using inﬂammation and joint
damage parameters.
. Inﬂammation parameters (Fig. 1):
1. Synovial proliferation (SP):
Synovitis by GSUS – synovial proliferation, deﬁned as
an abnormal hypoechoic intra-articular tissue that is
non-displaceable and poorly compressible visualized in
longitudinal and transversal planes28; The following 20
synovial sites in 10 joints were included: wrist (dorsal
carpal and ulnar carpal recess); second and third MCP
(dorsal side, palmar side); second and third PIP (palmar
side).
Synovial proliferation was analyzed in all sites, as fol-
lows:
- Semi-quantitative evaluation (SPSQ) – Grade 0
(absence), Grade 1 (small hypoechoic/anechoic line
beneath joint capsule), Grade 2 (joint capsule elevated
parallel to joint area) and Grade 3 (strong distension
of joint capsule)10,14;
- Qualitative evaluation (SPQ) – binary evaluation – 0
(absent) or 1 (present, if Grade 2 or 3 semi-quantitative
scores).
2. Synovial blood ﬂow:
Synovial blood ﬂow was evaluated by PD in each of the
intra-articular synovial sites. PD settings were standard-
ized with a pulse repetition frequency of 750 Hz and a
color-mode frequency of 12 MHz. Wall ﬁlters were set athighest value, not generating PD signals under the bone
cortex.
PD intra-articular signals were evaluated and graded on
a qualitative and semi-quantitative score:
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Fig. 1 – Inﬂammation parameters of US10. (A) Synovial proliferation grade 3; (B) synovitis by power Doppler grade 2; (C)
synovitis by power Doppler grade 3; (D) tenosynovitis by power Doppler. PP, proximal phalanx; MH,  metacarpal head; SP,
synovial proliferation; *, tenosynovitis.
quantitative score:- Semi-quantitative (PDSQ) – Grade 0 (no ﬂow in syn-
ovium), Grade 1 (single vessel signals); Grade 2
(conﬂuent vessel signals in less than half the area of
the synovium); Grade 3 (vessel signals in more than
half the area of the synovium)10;
- Qualitative (PDQ) – binary evaluation – 0 (absent) or 1
(present, if Grade 1 semi-quantitative score).
3. Tenosynovitis
Deﬁned as a hypoechoic or anechoic thickened tissue
with or without ﬂuid within the tendon sheath28;
The following tendons were evaluated: extensor digito-
rum communis; extensor carpi ulnaris; ﬂexor digitorum
communis, second and third ﬂexor tendons.
Tenosynovitis was evaluated and graded on a GSUS and
PDUS qualitative score:
-  Qualitative (TNGSQ) – binary evaluation – 0 (absent)
or 1 (present);
a
dc
PP
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Fig. 2 – Joint damage parameters of US10. (A) Bone erosion grade
grade 2; (D) cartilage damage grade 3. PP, proximal phalanx; MH,- Qualitative (TNPDQ) – binary evaluation – 0 (absent)
or 1 (present).
B. Joint damage parameters (Fig. 2):
1. Bone erosion
Erosion was deﬁned as an interruption of the bone sur-
face on two perpendicular planes.28
The location of each erosion was recorded based on the
bone involved, as follows:
- Dorsal quadrant of second and third metacarpal head
- Lateral quadrant of second metacarpal head
- Dorsal quadrant of second and third phalanx
- Ulnar styloid process
Bone erosions were graded on a qualitative and semi--  Semi-quantitative (BESQ) – Grade 0 (regular bone
surface), Grade 1 (irregular bone surface without
formation of defect seen on two planes), Grade 2
b
PP MH
USP
 2; (B) bone erosion grade 3 (arrow); (C) cartilage damage
 metacarpal head; USP, ulnar styloid process.
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Table 1 – US10: Score range for each ultrasound hand
parameter.
Ultrasound parameters – US10 Score range
10 Joints (second and third MCPs and PIPs and wrists)
Inﬂammation parameters
SPQ 0–16
SPSQ 0–48
PDQ 0–16
PDSQ 0–48
TNGSQ 0–10
TNPDQ 0–10
Joint damage parameters
BEQ 0–12
BESQ 0–36
CDQ 0–4
CDSQ 0–16
US10, ultrasound score of hand joints and wrists; MCP, metacar-
pophalangeal joint; PIP, proximal interphalangeal jont; SPQ, quali-
tative synovial proliferation; SPSQ, semi-quantitative synovial pro-
liferation; PDQ, qualitative power Doppler; PDSQ, semi-quantitative
power Doppler; TNGSQ, qualitative gray-scale tenosynovitis;
TNPDQ, qualitative power Doppler tenosynovitis; BEQ, qualitative
bone erosion; BESQ, semi-quantitative bone erosion; CDQ, qualita-
I
I
a
of follow up, seven patients (14.5%) continuing using MTX,tive cartilage damage; CDSQ, semi-quantitative cartilage damage.
(formation of defect on bone surface seen on two
planes) and Grade 3 (bone defect causing extensive
bone destruction)10;
- Qualitative (BEQ) – binary evaluation – 0 (absent) or 1
(present, if Grade 2 or 3 semi-quantitative scores).
2. Cartilage damage
US examinations were focused on the assessment of the
hyaline cartilage in the dorsal view of the second and
third metacarpal heads. Normal features of the hyaline
cartilage at the metacarpal head included two hyperec-
hoic sharp, regular and continuous margins delimiting
a homogenous anechoic band.29,30
Cartilage damage was evaluated using the following
semi-quantitative and qualitative scoring system:
- Semi-quantitative (CDSQ) – Grade 0 (normal hyaline
cartilage); Grade 1 (loss of sharpness of superﬁcial
margin of hyaline cartilage); Grade 2 (partial thickness
defect of cartilage layer); Grade 3 (full thickness defect
of cartilage layer with normal subchondral bone pro-
ﬁle); Grade 4 (complete loss of cartilage layer and
subchondral bone involvement).31,32
- Qualitative (CDQ) – binary evaluation – 0 (absent) or 1
(present, if Grade 2 or 3semi-quantitative scores).
The US10 scoring system analyzed 10 sonographic param-
eters, and each parameter was subdivided into qualitative
and semi-quantitative grades. The parameters were ana-
lyzed separately, as indicated in Table 1. These 10
parameters and 10-joints constituted the US10 system,
with the sum of all scores (Table 1).nterobserver  reliability
nterobserver reliability between two US operators was evalu-
ted on recorded images from 20 randomly chosen patients for 6;5 6(5):421–431 425
the inﬂammation and joint damage parameters of the joints
included in the US10 score. The captured images of each US10
item of 20 patients with a total of 200 images were evalu-
ated. The evaluation of the ultrasound images was performed
by a rheumatologist, with ﬁve years of experience in muscu-
loskeletal ultrasound.
Radiographic  evaluation
Posteroanterior X-rays of the patients’ hands were recorded
at baseline and after 12 months. The images were analyzed at
the end of the study by a radiologist who was blinded to the
other evaluations. The evaluation of hand X-rays was done by
a radiologist with 30 years of experience who was blind to the
clinical features, ultrasound results and identiﬁcation of the
patient. In the radiographic evaluation it was considered only
bone erosion. The presence of erosions was evaluated using
the scores proposed by van der Heijde et al.33 The correlation
between narrowing of joint space on X-rays and joint cartilage
damage on ultrasound was not analyzed.
Statistical  analysis
Statistical analysis was performed with the aid of the SPSS
program, version 17.0 (SPSS, Chicago, IL, USA). Data are
expressed as mean ± standard deviation. ANOVA was per-
formed to compare numerical variables repeated over time.
Correlations between changes in the different examination
modalities (clinical, laboratory and US) throughout the follow-
up period were evaluated by two-tailed Spearman’s correlation
coefﬁcients. Inter- and intra-reader agreement was calcu-
lated using kappa coefﬁcients between readers. The kappa
coefﬁcients were divided as follows: <0.0 = poor, 0–0.20 = slight,
0.21–0.40 = fair, 0.4–0.60 = moderate, 0.6–0.80 = substantial and
0.81–1.0 = almost perfect agreement.34 Comparisons between
X-ray and US regarding bone erosion were made using
the chi-square test, adjusted by the McNemar method.
The statistical signiﬁcance level was set to 5% (p < 0.05).
The data were analyzed using the intention-to-treat
principle.
Results
Patient  characteristics
Forty-eight patients (100% women) with a mean age of
47.7 ± 11.6 years (range: 22–65) and a mean disease dura-
tion of 7.5 ± 3.5 months (range: 2–12) were examined on four
occasions (baseline, 3, 6 and 12 months). Rheumatoid fac-
tor and anti-CCP were positive in 20 patients (41.7%) and 21
patients (43.8%), respectively. At baseline, 30 patients (62.5%)
met  the ACR criteria and 35 (72.9%) had ≥8.0 on the predic-
tive validation Leiden model score (Table 2). After 12 months41 (85.4%) received MTX + leﬂunomide, 25 (52%) had switched
to biological therapy and ﬁve (10.5%) had an indication to
receive a second biological agent at the ﬁnal evaluation
(12 months).
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Table 2 – Baseline demographic parameters, disease
related variables in 48 RA.
RA patients
(n = 48)
Age, years (mean ± SD) 47.7 ± 11.6
Gender (women/men) 48/0
Disease duration, months (mean ± SD) 7.5 ± 3.5
Rheumatoid factor (positive) (%) 20 (41.7%)
Anti-CCP (positive) (%) 21 (43.8%)
1987 ACR criteria (%) 30  (62.5%)
2010 ACR criteria (%) 48  (100%)
Leiden Model Score (%) 35 (72.9%)
RA, rheumatoid arthritis; ACR, American College of Rheumatology;
SD, standard deviation.
ing ten joints (2nd and 3rd MCPs and PIPs and wrists), denomi-Clinical,  laboratory  and  US10  parameters
Table 3 displays the US, clinical and laboratory data. A sig-
niﬁcant reduction in mean DAS28 score was found over
12 months (6.5–3.9; p < 0.05). The mean HAQ score also
decreased signiﬁcantly (1.4–0.7; p < 0.05). No signiﬁcant differ-
ences were found in mean CRP (14.0–6.9 mg/dliter; p > 0.05)
or ESR (30.6–24.3 mm/h; p > 0.05) levels over 12 months. All
US10 inﬂammation parameters decreased signiﬁcantly over
the course of the year. Mean SPQ and SPQSQ scores were
respectively 12.9 and 29.1 at baseline and decreased signif-
icantly after 12 months (7.0 and 14.2, respectively) (p < 0.05).
Mean baseline PDQ and PDSQ scores were 6.7 and 14.2, respec-
tively, and decreased signiﬁcantly and after 12 months (0.7
and 1.2, respectively) (p < 0.05). Mean TNGSQ and TNPDQ
scores reduced respectively from 2.9 and 2.3 at baseline
to 0.6 and 0.3 after 12 months (p < 0.05). Mean qualitative
and semi-quantitative bone erosion scores increased signif-
icantly over 12 months (4.7–6.0 and 9.7–12.7, respectively)
(p < 0.05). A signiﬁcant increase in the mean qualitative carti-
lage damage score occurred over 12 months (0.2–1.1; p < 0.05).
No signiﬁcant difference in the mean semi-qualitative car-
tilage damage score occurred over 12 months (1.2–2.5;
p = 0.14).
Baseline  and  longitudinal  correlation  between  US10
parameters
At baseline, all US10 inﬂammation parameter scores demon-
strated signiﬁcant correlations (p < 0.05) with each other (r
variation between 0.33 and 0.95). A signiﬁcant correlation
(p < 0.05) was found between changes in the SPSQ score
and changes in both the PDQ (r = 0.43) and PDSQ (r = 0.42)
scores and TNGSQ (r = 0.47) and TNPDQ (r = 0.40) scores over
12 months.
Baseline  and  longitudinal  correlations  between  US10,
clinical  and  laboratory  parametersAll US inﬂammation parameters (SPQ, SPSQ, PDQ, PDSQ,
TNGSQ and TNPDQ) demonstrated signiﬁcant correlations
with CRP levels at baseline (r = 0.31, r = 0.29, r = 0.38, r = 0.39, 0 1 6;5 6(5):421–431
r = 0.34 and r = 0.33, respectively) (p < 0.05). All PD (PDQ and
PDSQ) and tenosynovitis (TNGSQ and TNPDQ) scores were
signiﬁcantly correlated (p < 0.05) with DAS28 (r = 0.34, r = 0.34,
r = 0.35, r = 0.31, respectively). The GS and PD tenosynovi-
tis scores correlated signiﬁcantly (p < 0.05) with ESR (r = 0.50,
r = 0.40, respectively). No correlation was observed between
the change of the qualitative score of synovial prolifera-
tion (SPQ), and DAS 28 over time. However it was observed
correlation between the semi-quantitative score synovial
proliferation (SPSQ) and DAS28 scores. Changes in PD
and tenosynovitis scores were signiﬁcantly correlated with
changes in HAQ over 12 months (r = 0.32, r = 0.34, r = 0.40,
r = 0.32, respectively with p < 0.05). Changes in PD scores also
correlated with changes in CRP (r = 0.34, r = 0.29, respectively).
Changes in qualitative synovial proliferation and tenosyn-
ovitis scores (TNGSQ and TNPDQ) correlated with changes
in ESR (r = 0.29, r = 0.48, r = 0.49, respectively with p < 0.05).
There was no correlation between sonographic parameters
of joint damage (cartilage and erosion) and clinical and lab-
oratory variables. The correlations between the sonographic
parameters and clinical and laboratory variables are shown in
Table 4.
Inter-observer  reliability  regarding  US10  parameters
Mean kappa values for the qualitative and semi-quantitative
synovial proliferation scores were 0.49 and 0.21, respec-
tively (p < 0.05). Mean kappa values for PDQ, PDSQ, TNGSQ
and TNPDQ scores on stored images were 0.49, 0.56,
0.55 and 0.32, respectively (p < 0.05). Mean kappa values
for qualitative and semi-quantitative bone erosion scores
were 0.42 and 0.47, respectively (p < 0.05). Substantial agree-
ment between observers was found for the qualitative and
semi-quantitative cartilage damage scores (k = 0.79 and 0.82)
(p < 0.05).
Comparison  of  conventional  radiography  and  ultrasound
for bone  erosion  at  baseline  and  after  12  months
In 480 sites analyzed at baseline, radiography found ero-
sions in 54 sites (11.3%) and US found erosions in 150 sites
(31.3%). US detected 2.81-fold more  bone erosions than con-
ventional radiography in the 10 sites examined (p < 0.001).
After 12 months, US found 171 (39.80%) bone erosions and
radiography found 44 (10.20%) erosions in the 430 sites exam-
ined. The US detected 3.88-fold more  bone erosions than
conventional radiography in the 10 sites examined after 48
weeks of evaluation. Erosions were evaluated by the two
methods described in the same places and in the same
patients.
Discussion
The present study evaluated a novel US scoring system involv-nated the US10. The choice of these joints was based primarily
on the frequency with which they are affected in the early
years of RA.19–21 Previous studies have also proposed scoring
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Table 3 – Clinical, laboratory and US10 scores over time in relation to baseline evaluation.
Time points (weeks) Clinical parameters
DAS28 (n = 48) (Mean ± SD) HAQ (n = 48) (Mean ± SD)
T0 6.5 (±1.3) 1.4 (±0.7)
T12 4.5 (±1.7) 0.7 (±0.5)
T24 4.7 (±1.6) 0.8 (±0.7)
T48 3.9 (±1.4) 0.7 (±0.6)
pa 0.000 0.000
Laboratory parameters
ESR (n = 48) (Mean ± SD) CRP (n = 48) (Mean ± SD)
T0 30.6 (±3.5) 14.0 (±18.0)
T12 21.9 (±2.8) 8.4 (±11.4)
T24 24.0 (±2.6) 7.8 (±8.9)
T48 24.3 (±2.3) 6.9 (±12.1)
pa 0.058 0.325
US10 Parameters
SPQ (0–16) (Mean ± SD) SPSQ (0–48) (Mean ± SD)
T0 12.9 (±2.9) 29.1 (±8.4)
T12 4.2 (±3.4) 10.3 (±8.7)
T24 8.4 (±3.7) 17.3 (±6.8)
T48 7.0 (±3.9) 14.2 (±7.9)
pa 0.000 0.000
PDQ (0–16) (Mean ± SD) PDSQ (0–48) (Mean ± SD)
T0 6.7 (±4.1) 14.2 (±8.9)
T12 2.7 (±2.5) 5.0 (±5.1)
T24 2.3 (±2.1) 4.2 (±3.9)
T48 0.7 (±1.3) 1.2 (±2.3)
pa 0.000 0.000
TNGSQ (0–10) (Mean ± SD) TNPDQ (0–10) (Mean ± SD)
T0 2.9 (±2.5) 2.3 (±2.2)
T12 1.2 (±2.0) 1.1 (±2.0)
T24 1.7 (±2.0) 1.4 (±1.9)
T48 0.6 (±2.4) 0.3 (±1.0)
pa 0.00 0.000
BEQ (0–12) (Mean ± SD) BESQ (0–36) (Mean ± SD)
T0 4.7 (±1.8) 9.7 (±3.8)
T12 5.1 (±2.0) 10.9 (±4.4)
T24 5.9 (±1.4) 12.1 (±2.9)
T48 6.0 (±1.9) 12.7 (±3.8)
pa 0.003 0.010
CDQ (0–4) (Mean ± SD) CDSQ (0–12) (Mean ± SD)
T0 0.2 (±0.5) 1.2 (±1.8)
T12 0.6 (±1.1) 1.7 (±3.1)
T24 1.0 (±1.4) 2.4 (±3.3)
T48 1.1 (±1.4) 2.5 (±3.6)
pa 0.001 0.14
SD, standard deviation; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate (mm/hour); CRP, C-reactive protein
(mg/dliter); SPQ, qualitative synovial proliferation; SPSQ, semi-quantitative synovial proliferation; PDQ, qualitative power Doppler; PDSQ, semi-
quantitative power Doppler; TNGS, qualitative gray-scale tenosynovitis; TNPDQ, qualitative power Doppler tenosynovitis; BEQ, qualitative bone
erosion; BESQ, semi-quantitative bone erosion; CDQ, qualitative cartilage damage; CDSQ, semi-quantitative cartilage damage.
a ANOVA for repeated measurements.
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Table 4 – Baseline and longitudinal correlations between US10 parameters and both clinical and laboratory ﬁndings.
Baseline correlation between US10 parameters and both clinical and laboratory ﬁndings*
US10 DAS28 HAQ CRP ESR
r p r p r p r p
SPQ 0.06 0.683 −0.09 0.532 0.31 0.029 0.12 0.381
SPSQ 0.06 0.687 −0.06 0.657 0.29 0.039 0.08 0.155
PDQ 0.34 0.017 0.20 0.162 0.38 0.007 0.15 0.303
PDSQ 0.34 0.015 0.22 0.126 0.39 0.006 0.15 0.291
TNGSQ 0.35 0.014 0.14 0.320 0.34 0.015 0.50  0.000
TNPDQ 0.31 0.030 0.17 0.244  0.33 0.019 0.40 0.004
BEQ −0.15 0.280 −0.25 0.081 0.16 0.264 −0.05 0.692
BESQ −0.12 0.387 −0.23 0.107 0.14 0.333 −0.10 0.472
CDQ −0.14 0.344 0.02 0.878 0.08 0.558 −0.19 0.194
CDSQ −0.19 0.190 −0.09  0.501 0.04 0.787 −0.19 0.190
Correlations regarding longitudinal changes between US10 parameters and both clinical and laboratory ﬁndings
SPQ 0.26 0.071 0.21 0.171 0.16 0.250 0.29 0.042
SPSQ 0.34 0.018 0.26 0.079 0.14 0.334 0.27 0.060
PDQ 0.24 0.089 0.32 0.023 0.34 0.016 0.22 0.133
PDSQ 0.27 0.057 0.34 015 0.29 0.041 0.22 0.123
TNGSQ 0.54 0.000 0.40 0.004 0.21 0.136 0.48 0.000
TNPDQ 0.45 0.001 0.32 0.023 0.34 0.106 0.47 0.001
BEQ 0.02 0.879 0.04 0.772 −0.05 0.696 −0.09 0.522
BESQ 0.04 0.758 0.07 0.633 −0.03 0.796 0.02 0.879
CDQ −0.07 0.607 −0.07 0.612 0.18 0.203 0.09 0.513
CDSQ −0.09 0.538 −0.02 0.862 0.19 0.188 0.16 0.272
HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate (mm/h); CRP, C-reactive protein (mg/dliter); SPQ, qualitative synovial
proliferation; SPSQ, semi-quantitative synovial proliferation; PDQ, qualitative power Doppler; PDSQ, semi-quantitative power Doppler; TNGSQ,
qualitative gray-scale tenosynovitis; TNPDQ, qualitative power Doppler tenosynovitis; BEQ, qualitative bone erosion; BESQ, semi-quantitative
bone erosion; CDQ, qualitative cartilage damage; CDSQ, semi-quantitative cartilage damage; r, Spearman’s correlation.systems based on these joints and have demonstrated reliabil-
ity and correlations with clinical and laboratory ﬁndings.15–18
The US10 is composed of inﬂammatory and joint damage
parameters. Qualitative (binary) and semi-quantitative analy-
ses were used for the evaluation of synovial proliferation, PD
and joint damage. A qualitative score is simpler and faster
for clinical practice. However, according to OMERACT, the use
of a semi-quantitative scoring system offers greater sensi-
tivity for the assessment of changes throughout treatment
and demonstrates reproducibility in different studies.35 In the
present study, tenosynovitis was also evaluated with a qual-
itative score in gray scale and PD. Only a qualitative analysis
was performed, since there is no semi-quantitative score yet
validated for this parameter. Thus, the US10 is the ﬁrst global
US scoring system for the prospective analysis of changes in
inﬂammation and joint damage in patients with early AR with
no prior use of DMARDs.
Two studies have evaluated US inﬂammatory changes in
patients with early RA and no prior use of DMARDs. The ﬁrst
investigated the sensitivity and predictive value of PD changes
in 28 joints regarding clinical, laboratory and radiological
outcomes over a one-year period.36 However, no statistically
signiﬁcant change in PD was found and there was no pre-
determined treatment strategy applied to the patients, unlike
the present study. The second study investigated synovial pro-
liferation and PD in 44 joints in patients with early RA whoachieved clinical remission after the same treatment proto-
col. However, no change in US inﬂammatory parameters was
described with treatment over time in comparison to the base-
line evaluation.37 Moreover, neither of the studies cited used
a global US scoring system or investigated the presence of
tenosynovitis.
Previous studies have assessed US changes over time using
a global scoring system on patients with established RA or
other chronic inﬂammatory joint diseases.15–18 A simpliﬁed
12-joint scoring system proposed by Naredo et al. (2008)
was applied to patients with RA with mean disease dura-
tion of 111 months.15 Dougados et al. (2010) investigated
different US scoring systems for synovial proliferation and
PD in 20, 28 and 38 joints of patients with RA with mean
disease duration of 10 years17 and found changes in the
inﬂammatory parameters over time in relation to the baseline
evaluation (as in the present study), but did not investigate
tenosynovitis. Backhaus et al. (2009) employed a seven-joint
ultrasound score to follow up changes in different inﬂamma-
tory joint diseases (RA, psoriatic arthritis, spondyloarthritis)
and found statistically signiﬁcant improvements in synovitis
parameters (synovial proliferation and PD) and tenosynovi-
tis after three and six months in comparison to the baseline
evaluation.16
The evaluation of tenosynovitis in the joints studied in
the US10 system (wrist and MCPs) revealed a statistically
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igniﬁcant improvement over a 48-week period. A recent
tudy38 reports that the sum of gray-scale and PD scores of
he tendons of the long ﬂexors of the ﬁngers and ulnar exten-
or of the carpus was sensitive to change, with a reduction in
cores after 12 months in patients with RA using adalimumab.
owever, unlike the present study, there was no assessment
f the tendons of the digitorum communis ﬂexors of the
ngers and the patients had long disease duration. There
s evidence that patients in the early stage of the disease
xperience greater tenosynovitis, especially in the digitorum
ommunis ﬂexors.7,8
This study showed in addition to the correlation between
endon score and disease activity, a correlation between the
mprovements of tendon score with the improvement of
atient’s function, analyzed by HAQ. Thus, one may postulate
hat the tendons of the hands and wrists should be included
n the follow up of patients with RA, as demonstrated by the
resent US ﬁndings.
The only previous US scoring system to evaluate bone ero-
ions was the seven-joint system proposed by Backhaus et al.
2009), which revealed no changes over a six-month period
unlike in the present study).16 However, as mentioned above,
he authors evaluated patients with different inﬂammatory
oint diseases, including established RA, rather than patients
ith early RA.
Over the 48-week period, the change in the semi-
uantitative synovial proliferation score was moderately
orrelated with changes in PD and tenosynovitis and changes
n these latter two variables were correlated with each other.
hese ﬁndings lend support to the hypothesis that a reduc-
ion occurs in the entire intra-articular and peri-articular
nﬂammatory process following the establishment of ade-
uate treatment and underscores the importance of the
ssessment of tenosynovitis as a US measure in patients with
arly RA.
The US10 proved to be correlated with disease activity
arameters (CRP and DAS28). These correlations have also
een demonstrated in other US scoring systems.12,15–18,36
aredo et al. (2005) found a strong correlation between CRP
nd the number of joints with synovial proliferation and PD
ignals in 60 joints in patients with established RA. The same
uthors found moderate correlations between synovial prolif-
ration and both CRP (r = 0.33) and the DAS28 (r = 0.43) as well
s between PD and both CRP (r = 0.33) and DAS28 (r = 0.48), in 28
oints of patients with RA with less than one year of symptoms
t the onset of treatment with DMARDs.12 These correlations
re similar to those found with the US10 scoring system in
he present study. The global 12-joint US scoring system vali-
ated by Naredo et al. (2008) identiﬁed moderate correlations
etween synovial proliferation and both PD (r = 0.55) and the
AS28 (r = 0.38).15 Perruconi et al. (2012) also found moder-
te correlations between the number of joints with synovitis
nd both the DAS28 (r = 0.53) and CRP (r = 0.51) in a simpliﬁed
ix-joint scoring system administered to patients with estab-
ished RA.18 It should be stressed that the US10 scoring system
as administered to a small number of joints in patients with
arly RA and no prior use of DMARDs and demonstrated a
lose relationship between the US ﬁndings and disease activ-
ty criteria, allowing better management of these patients in
linical practice. 6;5 6(5):421–431 429
The correlations found in the present study are in disagree-
ment with those reported in previous cohorts with early RA.
Naredo et al. (2007) found moderate cross-sectional correla-
tions between joint count and disease activity variables (CRP
and DAS28) at baseline as well as at six, nine and 12 months
of follow up, but found no longitudinal correlations between
changes in US evaluation and changes in the clinical and lab-
oratory ﬁndings.
In the present study, a correlation was also found
between the change in active synovitis (assessed based
on PD parameters) and a changes in the HAQ score. This
ﬁnding strongly supports the hypothesis of an association
between an improvement in the synovial inﬂammatory pro-
cess and improvements in both function and quality of
life.
Few studies have investigated interobserver reliability in US
scoring systems. In the 12-joint system proposed by Naredo
et al. (2008), the authors found moderate interobserver agree-
ment (k = 0.5) regarding the presence of synovial proliferation
(which is similar to the agreement found in the present study)
and a stronger correlation than that reported in the present
study between synovial proliferation and PD (r = 0.8).15 In the
seven-joint system proposed by Backhaus et al. (2009), mod-
erate agreement was found regarding the identiﬁcation of
synovial proliferation (k = 0.62), with somewhat lesser agree-
ment (k = 0.55) regarding the semi-quantitative score (0–3)16
and better agreement (k = 0.67) regarding the qualitative PD
variable, which is similar to that of the present study. The
same study was the only previous investigation to address
interobserver reliability in the detection of bone erosion, for
which moderate agreement was found (k = 0.56).16 Regarding
joint damage, the US10 is the ﬁrst global scoring system to
address this evaluation, with excellent agreement found for
the qualitative and semi-quantitative variables (k = 0.79 and
0.82, respectively).
The ﬁndings of the present study indicate that the pro-
posed US10 is a valid scoring system for the follow up of
inﬂammation and joint damage in patients with early RA,
demonstrating signiﬁcant correlations with clinical and lab-
oratory ﬁndings as well as correlations between the changes
in this score and both clinical and functional measures of the
disease following a speciﬁc treatment protocol.
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